Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Body Radiation Therapy With Consolidation Durvalumab in High-Risk Early-Stage Non-Small Cell Lung Cancer - A Phase II Single-Arm Trial

NCT04716946 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04716946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04716946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Body Radiation Therapy With Consolidation Durvalumab in High-Risk Early-Stage Non-Small Cell Lung Cancer - A Phase II Single-Arm Trial
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 27, 2021
Completion date
February 28, 2027
Enrollment
13 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell lung cancer, non-small cell lung cancer stage i, non-small cell lung cancer stage ii, non-small cell lung cancer stage iii, non-small cell lung cancer stage iiia, nsclc, pd-l1 gene mutation